{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:01:25Z","timestamp":1783576885064,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Intercept Pharmaceuticals, Inc"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jhepr.2020.100191","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T19:24:14Z","timestamp":1601407454000},"page":"100191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis"],"prefix":"10.1016","volume":"3","author":[{"given":"Maren H.","family":"Harms","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon M.","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarosa","family":"Floreani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlyn J.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Par\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Liberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Smoot","family":"Malecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pencek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"MacConell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2020.100191_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100191_bib2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100191_bib3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ajg.2017.440","article-title":"Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome","volume":"113","author":"Harms","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2020.100191_bib4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100191_bib5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100191_bib6","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to\u00a0predict outcomes of patients with primary biliary cirrhosis receiving\u00a0ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100191_bib7","series-title":"OCALIVA (Obeticholic Acid) Prescribing Information","year":"2018"},{"key":"10.1016\/j.jhepr.2020.100191_bib8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2020.100191_bib9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A\u00a0simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100191_bib10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3748\/wjg.15.591","article-title":"Biochemical markers for non-invasive assessment of disease stage in patients with primary biliary cirrhosis","volume":"15","author":"Alempijevic","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2020.100191_bib11","doi-asserted-by":"crossref","first-page":"7863","DOI":"10.3748\/wjg.v23.i44.7863","article-title":"Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis","volume":"23","author":"Cheung","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2020.100191_bib12","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2014.01.029","article-title":"Optimising risk stratification in primary biliary cirrhosis: AST\/platelet ratio index predicts outcome independent of ursodeoxycholic acid response","volume":"60","author":"Trivedi","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100191_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100191_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/hep4.1180","article-title":"Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis","volume":"2","author":"Carbone","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2020.100191_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/apt.15060","article-title":"Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades","volume":"49","author":"Harms","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2020.100191_bib16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.cgh.2017.09.062","article-title":"Twenty-year comparative analysis of patients with autoimmune liver diseases on transplant waitlists","volume":"16","author":"Webb","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100191_bib17","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/hep.30552","article-title":"Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis","volume":"70","author":"Honda","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100191_bib18","first-page":"154","article-title":"Update on new drugs and those in development for the treatment of primary biliary cholangitis","volume":"14","author":"Bahar","year":"2018","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.jhepr.2020.100191_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bpg.2018.06.006","article-title":"Risk stratification and prognostic modelling in primary biliary cholangitis","volume":"34\u201335","author":"Goet","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555920301257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555920301257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:25:11Z","timestamp":1762899911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555920301257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S2589555920301257"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2020.100191","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2020.100191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100191"}}